Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon gamma plus TCH versus TCH alone as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR1900025247Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon gamma-1b, docetaxel, carboplatin and trastuzumab in breast cancer (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathologic complete response rate. Started Aug 2019; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900025247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025247.